Rocket One Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Rocket One Inc. (RKTO) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $1.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14
- Rocket One Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$2.20M, a 151.46% decline year-over-year.
- Rocket One Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $4.28M.
- Rocket One Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$1.72M, a 126.03% decline year-over-year.
- Rocket One Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $6.62M.
- Rocket One Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$793.22K.
- Rocket One Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$2.24M, a 177.88% decline from fiscal 2023.
- Rocket One Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $2.87M.
- Rocket One Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$2.10M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.64M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$2.20M 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | -$793.22K 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $807.02K 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $1.97M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | $4.28M 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | -$2.24M 10-K · filed 2026-03-27 | |||
| 2024-09-30 | -$1.27M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $366.62K 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | -$1.72M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $2.87M 10-K · filed 2025-03-28 | |||
| 2023-09-30 | $5.94M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $5.17M 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | $6.62M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$2.10M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $406.51K 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $2.79M 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |